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In recent years, developments in the fi eld of treat-
ment-resistant depression have not only brought about 
improved defi nition and classifi cation, but also have led 
to an increase in our knowledge regarding the etiology 
and determinants of treatment resistance. A number of 
novel treatment strategies have been suggested which 
require critical evaluation before they are integrated 
into an evidence-based therapeutic concept. Th e pres-
ent contribution provides an overview of these devel-
opments and reveals promising research perspectives 
which will extend our knowledge of the etiology and 
pathogenesis of depressive disorders and may thereby 
lead to the development of innovative therapeutic strat-
egies for treatment-resistant depression. 
Up to now, therapeutic concepts in treatment-
resistant depression have mainly concentrated on 
the restitution of neurotransmitter balance between 
monoaminergic and cholinergic systems. But a num-
ber of factors have been neglected, some of which I 
will address here. 
Several lines of evidence implicate dopamine in the 
pathogenesis and treatment of depression. First, there 
are consistent fi ndings which point to decreased dop-
amine neurotransmission in depressed patients. Levels 
of homovanillic acid, the major metabolite of dopamine, 
have been shown to be reduced in the cerebrospinal 
fl uid of depressed patients. A second line of evidence 
comes from studies of brain dopaminergic pathways. 
Th e mesolimbic and mesocortical pathways have been 
termed the ‚brain reward system’ and this system ap-
pears to be aff ected by major depressive episodes. 
Pharmacological experiments in rodents, suggest 
that antidepressant drugs of diff erent classes and pos-
sibly also electroconvulsive treatment, increase the 
binding potential of dopamine D2-like agonists in the 
nucleus accumbens. Th is supersensitivity to dopamine 
has behavioural eff ects and might mediate at least 
some of the antidepressant properties of these somatic 
antidepressant treatments. 
In the serotonergic system, S-adenosyl methionine 
(SAME) augmentation has been shown to be an eff ective 
adjunctive treatment strategy (Papakostas et al., 2010). 
Guillin and coworkers (2001, 2003) reported from 
animal experiments, that in the hippocampus, some 
cortical areas, and possibly the ventral tegmental area, 
both serotonergic and noradrenergic antidepressant 
drugs increase Cyclic AMP response element binding 
protein (CREB) phosphorylation as well as probably 
other pathways. Th is activated CREB drives Brain-de-
rived neurotrophic factor (BDNF) expression. BDNF 
has been shown to activate dopamine D3 receptor 
expression in the nucleus accumbens. As D2 and D3 
receptors belong to the same receptor family, D2-like 
receptor agonists might be particularly eff ective as an 
augmentation to traditional antidepressant drugs. 
Glutamate receptor stimulation is involved in pro-
cesses of learning and memory, as well as in other plas-
tic changes in the CNS such as synapse induction and 
elimination during development. On the other hand, 
glutamatergic dysfunction is characterized by exces-
sive accumulation of extracellular glutamate, which, 
if not effi  ciently removed from the synaptic cleft by 
glutamate transporters, leads to excitotoxic neuronal 
cell death due to the overactivation of postsynaptic 
glutamate receptors. Th e three major mechanisms of 
the glutamatergic system that can be targeted phar-
macologically are the presynaptic glutamate release 
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mechanisms‚ postsynaptic glutamate receptor activa-
tion, and the glutamate uptake mechanisms (Krystal, 
2010; Li et al., 2010). For depression, amantadine, a 
nonselective NMDA receptor antagonist, has been 
shown to enhance the antidepressant-like eff ects of 
typical antidepressants in animal models (Rogoz et 
al. 2002, 2004). In addition, AMPA receptor agonists 
are proposed to augment typical antidepressant eff ects 
in animal models (Li et al. 2003; Pilc et al. 2002). 
A number of drugs are available that target presyn-
aptic glutamate release. Riluzole is an antiglutamater-
gic agent that is believed to reduce extra-synaptic 
glutamate levels by decreasing presynaptic glutamate 
release. Riluzole, which has been successfully used in 
amyotrophic lateral sclerosis (ALS) patients (Miller 
et al. 2003; Rivière et al. 1998), has demonstrated its 
effi  cacy in monotherapy in treatment-resistant major 
depression as well as an augmenting agent in bipo-
lar depression (Zarate et al, 2004, 2005). Similarly, 
lamotrigine, also a drug believed to reduce presyn-
aptic glutamate release, has been shown to be eff ec-
tive in the treatment of bipolar depression when used 
as monotherapy or as an augmentation agent. Th ese 
studies lend support to the value of investigating anti-
glutamatergic drugs as an approach to the manage-
ment of treatment-resistant depression. Recent stud-
ies suggest that increasing glutamate uptake off ers yet 
another new therapeutic target for neuroprotection 
against excessive neurotoxic levels of extracellular glu-
tamate (Salvadore and Zarate, 2010).
Chronic lithium treatment increases the uptake of 
glutamate and also can reduce the increase in intracel-
lular calcium that occurs as a result of NMDA recep-
tor activation. Th ese actions may provide mechanisms 
for lithium to reduce excitatory neurotransmission and 
contribute to lithium‘s neuroprotective eff ects against 
certain excitatory insults. 
Th e term “neuroplasticity“ subsumes diverse pro-
cesses of vital importance by which the brain per-
ceives, adapts to and responds to a variety of internal 
and external stimuli. Th e manifestations of neuro-
plasticity in the adult CNS have been characterized 
as including alterations of dendritic function, synaptic 
remodeling, long-term potentiation (LTP), axonaI 
sprouting, neurite extension, synaptogenesis, and even 
neurogenesis. 
It has recently been proposed that impairments of 
neuroplasticity and cellular resilience may underlie 
the pathophysiology of mood disorders (Manji et al., 
2000), and further that optimal long-term treatment 
for these severe illnesses may only be achieved by the 
early and aggressive use of agents with neurotrophic 
and/or neuroprotective eff ects, alongside the primary, 
symptomatic treatments. Such treatment modalities, 
via their eff ects on critical molecules involved in cell 
survival and cell death pathways, such as CREB, 
BDNF, Bcl-2, p53 and MAP kinases, have the po-
tential to enhance neuroplasticity and cellular resil-
ience, and thereby modulate the long-term course and 
trajectory of these devastating illnesses. 
Genetic and neurodevelopmental factors, repeated 
aff ective episodes and likely elevations of glucocor-
ticoids and illness progression may all contribute to 
the impairments of cellular resilience, volumetric re-
ductions, and cell death or atrophy observed in mood 
disorders. Bcl-2 attenuates apoptosis by sequestering 
proforms of death-driving cysteine proteases (called 
caspases), by preventing the release of mitochondrial 
apoptogenic factors, such as calcium, cytochrome C 
and apoptosis-inducing factor, AIF, into the cyto-
plasm, and by enhancing mitochondrial calcium up-
take. Moreover, Bcl-2 acts on mitochondria to stabi-
lize membrane integrity and to prevent opening of the 
permeability transition pore. 
Lithium, via its eff ects on Bcl-2 and p53, may exert 
eff ects on the mitochondrial permeability transition 
pore, a key event in cell death. Lithium and valproic 
acid also inhibit GSK-3β, a biochemical eff ect shown 
to have neuroprotective consequences (Jope and Bi-
jur, 2002; O`Brien and Klein, 2007). Valproic acid 
also activates the ERK MAP kinase pathway, which 
may play a major role in neurotrophic eff ects and neu-
rite outgrowth. Th e ERK MAP kinase cascade also 
increases the expression of Bcl-2 via its eff ects on 
CREB. Antidepressants regulate the expression of 
BDNF, and its receptor, tyrosine kinase receptor for 
BDNF (trk B; Duman et al., 2007).
With regard to glial cells, there is a growing ap-
preciation of the critical roles of glia in regulating 
synaptic glutamate levels, CNS energy homeostasis, 
liberation of trophic factors, and indeed the very exis-
tence of synaptic networks of neurons and glia, all of 
which suggest that the prominent glia loss observed in 
major depressive disorder and bipolar disorder may be 
Acta Clin Croat (Suppl. 2) 2011; 4th international epilepsy symposium in Pula – how to start seizure treatment
86 Acta Clin Croat,  Vol. 50,  (Suppl) No. 2,  2011
integral to the pathophysiology of these disorders, and 
therefore worthy of further study.
Further lines of research have been suggested in 
the fi eld of aff ective disorders during recent years 
(Krishnan and Nestler, 2010; Holsboer, 2010), among 
them functional genetic variation of neuropeptide Y 
(Mickey et al., 2011), the role of proteomics (Martins 
– de Souza et al., 2010), and – fi nally – the develop-
ment of personalized medicine (Bartova et al, 2010; 
Schwab et al., 2010). 
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